Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
Byeong Geun SongMyung Ji GohWon Seok KangDong Hyun SinnGeum-Youn GwakMoon Seok ChoiJoon Hyeok LeeYong-Han PaikPublished in: Gut and liver (2024)
Atezolizumab and bevacizumab demonstrated real-world efficacy in the treatment of advanced HCC, with ORRs and DCRs aligning with those observed in clinical trials. Variations in PFS and ORR based on specific risk factors highlight the potential of atezolizumab and bevacizumab in precision medicine for advanced HCC.